Abstract
Drug combinations are frequently used to improve clinical efficacy, to minimize toxicity, and to reduce the development of resistance. Here, we investigated the growth inhibitory activity of the CDK4/6 inhibitor abemaciclib in combination with other targeted agents. Twelve well-characterized patient-.derived cancer cell lines from the NCI Patient-Derived Models Repository (https://pdmr.cancer.gov/models/database.htm) and seven established cell lines from the NCI-60 human tumor cell line panel were grown as multicellular 3D complex spheroids.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
